Case Journey | ROS1: Transforming NSCLC Patient Outcomes through Precision Testing and Targeted Treatment

In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC).  Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 variants, and the latest advancements in ROS1-targeted therapy. These cases underscore the importance of aligning therapeutic approaches with evidence-based strategies and clinical guidelines by illustrating their direct impact on patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.